APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angina Pectoris Medication

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Angina Pectoris Medication Market Analysis and Forecast 2026-2032

27 December 2025191 pages

Choose your research edition.

Industry ResearchAngina Pectoris Medication Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Angina Pectoris Medication Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Angina Pectoris Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angina Pectoris Medication Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Angina Pectoris Medication Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Angina Pectoris Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Angina Pectoris Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Angina Pectoris Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Angina Pectoris Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Angina Pectoris Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Angina Pectoris Medication include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Gilead Sciences, Pfizer Inc., GlaxoSmithKline Plc., Otsuka Pharmaceutical Co., Ltd. and Boehringer Ingelheim International GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Angina Pectoris Medication, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Angina Pectoris Medication, also provides the revenue of main regions and countries. Of the upcoming market potential for Angina Pectoris Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Angina Pectoris Medication revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Angina Pectoris Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Angina Pectoris Medication revenue, projected growth trends, production technology, application and end-user industry.

Angina Pectoris Medication Segment by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly and Company

Gilead Sciences

Pfizer Inc.

GlaxoSmithKline Plc.

Otsuka Pharmaceutical Co., Ltd.

Boehringer Ingelheim International GmbH

Bayer AG

Amgen Inc.

AstraZeneca

Angina Pectoris Medication Segment by Type

Beta Blockers

Calcium Antagonists

Anticoagulants

Anti-Platelets

Others

Angina Pectoris Medication Segment by Application

Hospitals

Clinics

Others

Angina Pectoris Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angina Pectoris Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angina Pectoris Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angina Pectoris Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Angina Pectoris Medication in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Angina Pectoris Medication company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Angina Pectoris Medication revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Angina Pectoris Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Beta Blockers Major Player Table 3. Calcium Antagonists Major Player Table 4. Anticoagulants Major Player Table 5. Anti-Platelets Major Player Table 6. Others Major Player Table 7. Global Angina Pectoris Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Angina Pectoris Medication Industry Trends Table 12. Angina Pectoris Medication Industry Drivers Table 13. Angina Pectoris Medication Industry Opportunities and Challenges Table 14. Angina Pectoris Medication Industry Restraints Table 15. Global Angina Pectoris Medication Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Angina Pectoris Medication Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Angina Pectoris Medication Market Share by Region (2021-2026) Table 18. Global Angina Pectoris Medication Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Angina Pectoris Medication Market Share by Region (2027-2032) Table 20. Global Angina Pectoris Medication Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Angina Pectoris Medication Revenue Market Share by Players (2021-2026) Table 22. Global Angina Pectoris Medication Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Angina Pectoris Medication Key Players Headquarters & Area Served Table 24. Global Angina Pectoris Medication Players, Product Type & Application Table 25. Global Angina Pectoris Medication Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Angina Pectoris Medication by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Angina Pectoris Medication Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Angina Pectoris Medication Revenue Market Share by Type (2021-2026) Table 32. Global Angina Pectoris Medication Revenue Market Share by Type (2027-2032) Table 33. Global Angina Pectoris Medication Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Angina Pectoris Medication Revenue Market Share by Application (2021-2026) Table 37. Global Angina Pectoris Medication Revenue Market Share by Application (2027-2032) Table 38. Sanofi S.A. Company Information Table 39. Sanofi S.A. Business Overview Table 40. Sanofi S.A. Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi S.A. Angina Pectoris Medication Product Portfolio Table 42. Sanofi S.A. Recent Development Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Novartis AG Angina Pectoris Medication Product Portfolio Table 47. Novartis AG Recent Development Table 48. Merck & Co., Inc. Company Information Table 49. Merck & Co., Inc. Business Overview Table 50. Merck & Co., Inc. Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Merck & Co., Inc. Angina Pectoris Medication Product Portfolio Table 52. Merck & Co., Inc. Recent Development Table 53. Eli Lilly and Company Company Information Table 54. Eli Lilly and Company Business Overview Table 55. Eli Lilly and Company Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Eli Lilly and Company Angina Pectoris Medication Product Portfolio Table 57. Eli Lilly and Company Recent Development Table 58. Gilead Sciences Company Information Table 59. Gilead Sciences Business Overview Table 60. Gilead Sciences Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Gilead Sciences Angina Pectoris Medication Product Portfolio Table 62. Gilead Sciences Recent Development Table 63. Pfizer Inc. Company Information Table 64. Pfizer Inc. Business Overview Table 65. Pfizer Inc. Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Pfizer Inc. Angina Pectoris Medication Product Portfolio Table 67. Pfizer Inc. Recent Development Table 68. GlaxoSmithKline Plc. Company Information Table 69. GlaxoSmithKline Plc. Business Overview Table 70. GlaxoSmithKline Plc. Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio Table 72. GlaxoSmithKline Plc. Recent Development Table 73. Otsuka Pharmaceutical Co., Ltd. Company Information Table 74. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 75. Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio Table 77. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 78. Boehringer Ingelheim International GmbH Company Information Table 79. Boehringer Ingelheim International GmbH Business Overview Table 80. Boehringer Ingelheim International GmbH Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio Table 82. Boehringer Ingelheim International GmbH Recent Development Table 83. Bayer AG Company Information Table 84. Bayer AG Business Overview Table 85. Bayer AG Angina Pectoris Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Bayer AG Angina Pectoris Medication Product Portfolio Table 87. Bayer AG Recent Development Table 88. Amgen Inc. Company Information Table 89. Amgen Inc. Business Overview Table 90. Amgen Inc. Angina Pectoris Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Amgen Inc. Angina Pectoris Medication Product Portfolio Table 92. Amgen Inc. Recent Development Table 93. AstraZeneca Company Information Table 94. AstraZeneca Business Overview Table 95. AstraZeneca Angina Pectoris Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. AstraZeneca Angina Pectoris Medication Product Portfolio Table 97. AstraZeneca Recent Development Table 98. North America Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 101. North America Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 102. North America Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. North America Angina Pectoris Medication Revenue by Country (2021-2026) & (US$ Million) Table 104. North America Angina Pectoris Medication Revenue by Country (US$ Million) & (2027-2032) Table 105. Europe Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 108. Europe Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 109. Europe Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Angina Pectoris Medication Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Angina Pectoris Medication Revenue by Country (US$ Million) & (2027-2032) Table 112. China Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 113. China Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 114. China Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 115. China Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 117. Asia Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 118. Asia Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 119. Asia Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Angina Pectoris Medication Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Asia Angina Pectoris Medication Revenue by Region (US$ Million) & (2021-2026) Table 122. Asia Angina Pectoris Medication Revenue by Region (US$ Million) & (2027-2032) Table 123. SAMEA Angina Pectoris Medication Revenue by Type (2021-2026) & (US$ Million) Table 124. SAMEA Angina Pectoris Medication Revenue by Type (2027-2032) & (US$ Million) Table 125. SAMEA Angina Pectoris Medication Revenue by Application (2021-2026) & (US$ Million) Table 126. SAMEA Angina Pectoris Medication Revenue by Application (2027-2032) & (US$ Million) Table 127. SAMEA Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. SAMEA Angina Pectoris Medication Revenue by Country (2021-2026) & (US$ Million) Table 129. SAMEA Angina Pectoris Medication Revenue by Country (US$ Million) & (2027-2032) Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Angina Pectoris Medication Image Figure 2. Global Angina Pectoris Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angina Pectoris Medication Market Size Share 2021 VS 2025 VS 2032 Figure 4. Beta Blockers Image Figure 5. Calcium Antagonists Image Figure 6. Anticoagulants Image Figure 7. Anti-Platelets Image Figure 8. Others Image Figure 9. Global Angina Pectoris Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Angina Pectoris Medication Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Angina Pectoris Medication Market Size (US$ Million) & (2021-2032) Figure 15. Global Angina Pectoris Medication Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Angina Pectoris Medication Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Angina Pectoris Medication Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Angina Pectoris Medication Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Angina Pectoris Medication Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Angina Pectoris Medication Revenue Market Share by Type (2021-2032) Figure 22. Global Angina Pectoris Medication Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Angina Pectoris Medication Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Angina Pectoris Medication Revenue Market Share by Application (2021-2032) Figure 25. North America Angina Pectoris Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Angina Pectoris Medication Revenue Share by Type (2021-2032) Figure 27. North America Angina Pectoris Medication Revenue Share by Application (2021-2032) Figure 28. North America Angina Pectoris Medication Revenue Share by Country (2021-2032) Figure 29. United States Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Angina Pectoris Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Angina Pectoris Medication Revenue Share by Type (2021-2032) Figure 34. Europe Angina Pectoris Medication Revenue Share by Application (2021-2032) Figure 35. Europe Angina Pectoris Medication Revenue Share by Country (2021-2032) Figure 36. Germany Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Angina Pectoris Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Angina Pectoris Medication Revenue Share by Type (2021-2032) Figure 46. China Angina Pectoris Medication Revenue Share by Application (2021-2032) Figure 47. Asia Angina Pectoris Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Angina Pectoris Medication Revenue Share by Type (2021-2032) Figure 49. Asia Angina Pectoris Medication Revenue Share by Application (2021-2032) Figure 50. Asia Angina Pectoris Medication Revenue Share by Region (2021-2032) Figure 51. Japan Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Angina Pectoris Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Angina Pectoris Medication Revenue Share by Type (2021-2032) Figure 59. SAMEA Angina Pectoris Medication Revenue Share by Application (2021-2032) Figure 60. SAMEA Angina Pectoris Medication Revenue Share by Country (2021-2032) Figure 61. Brazil Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Angina Pectoris Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Antagonists
  • Anticoagulants
  • Anti-Platelets
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Amgen Inc.
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Angina Pectoris Medication Market by Type
  3. 1.2.1 Global Angina Pectoris Medication Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Beta Blockers
  5. 1.2.3 Calcium Antagonists
  6. 1.2.4 Anticoagulants
  7. 1.2.5 Anti-Platelets
  8. 1.2.6 Others
  9. 1.3 Angina Pectoris Medication Market by Application
  10. 1.3.1 Global Angina Pectoris Medication Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Angina Pectoris Medication Market Dynamics
  1. 2.1 Angina Pectoris Medication Industry Trends
  2. 2.2 Angina Pectoris Medication Industry Drivers
  3. 2.3 Angina Pectoris Medication Industry Opportunities and Challenges
  4. 2.4 Angina Pectoris Medication Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Angina Pectoris Medication Market Perspective (2021-2032)
  2. 3.2 Global Angina Pectoris Medication Growth Trends by Region
  3. 3.2.1 Global Angina Pectoris Medication Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Angina Pectoris Medication Market Size by Region (2021-2026)
  5. 3.2.3 Global Angina Pectoris Medication Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Angina Pectoris Medication Revenue by Players
  2. 4.1.1 Global Angina Pectoris Medication Revenue by Players (2021-2026)
  3. 4.1.2 Global Angina Pectoris Medication Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Angina Pectoris Medication Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Angina Pectoris Medication Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Angina Pectoris Medication Key Players Headquarters & Area Served
  7. 4.4 Global Angina Pectoris Medication Players, Product Type & Application
  8. 4.5 Global Angina Pectoris Medication Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Angina Pectoris Medication Market CR5 and HHI
  11. 4.6.3 2025 Angina Pectoris Medication Tier 1, Tier 2, and Tier 3
5 Angina Pectoris Medication Market Size by Type
  1. 5.1 Global Angina Pectoris Medication Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 5.3 Global Angina Pectoris Medication Revenue Market Share by Type (2021-2032)
6 Angina Pectoris Medication Market Size by Application
  1. 6.1 Global Angina Pectoris Medication Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Angina Pectoris Medication Revenue by Application (2021-2032)
  3. 6.3 Global Angina Pectoris Medication Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi S.A.
  2. 7.1.1 Sanofi S.A. Company Information
  3. 7.1.2 Sanofi S.A. Business Overview
  4. 7.1.3 Sanofi S.A. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi S.A. Angina Pectoris Medication Product Portfolio
  6. 7.1.5 Sanofi S.A. Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Angina Pectoris Medication Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Merck & Co., Inc.
  14. 7.3.1 Merck & Co., Inc. Company Information
  15. 7.3.2 Merck & Co., Inc. Business Overview
  16. 7.3.3 Merck & Co., Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co., Inc. Angina Pectoris Medication Product Portfolio
  18. 7.3.5 Merck & Co., Inc. Recent Developments
  19. 7.4 Eli Lilly and Company
  20. 7.4.1 Eli Lilly and Company Company Information
  21. 7.4.2 Eli Lilly and Company Business Overview
  22. 7.4.3 Eli Lilly and Company Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly and Company Angina Pectoris Medication Product Portfolio
  24. 7.4.5 Eli Lilly and Company Recent Developments
  25. 7.5 Gilead Sciences
  26. 7.5.1 Gilead Sciences Company Information
  27. 7.5.2 Gilead Sciences Business Overview
  28. 7.5.3 Gilead Sciences Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Gilead Sciences Angina Pectoris Medication Product Portfolio
  30. 7.5.5 Gilead Sciences Recent Developments
  31. 7.6 Pfizer Inc.
  32. 7.6.1 Pfizer Inc. Company Information
  33. 7.6.2 Pfizer Inc. Business Overview
  34. 7.6.3 Pfizer Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Inc. Angina Pectoris Medication Product Portfolio
  36. 7.6.5 Pfizer Inc. Recent Developments
  37. 7.7 GlaxoSmithKline Plc.
  38. 7.7.1 GlaxoSmithKline Plc. Company Information
  39. 7.7.2 GlaxoSmithKline Plc. Business Overview
  40. 7.7.3 GlaxoSmithKline Plc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline Plc. Angina Pectoris Medication Product Portfolio
  42. 7.7.5 GlaxoSmithKline Plc. Recent Developments
  43. 7.8 Otsuka Pharmaceutical Co., Ltd.
  44. 7.8.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  45. 7.8.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  46. 7.8.3 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Otsuka Pharmaceutical Co., Ltd. Angina Pectoris Medication Product Portfolio
  48. 7.8.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  49. 7.9 Boehringer Ingelheim International GmbH
  50. 7.9.1 Boehringer Ingelheim International GmbH Company Information
  51. 7.9.2 Boehringer Ingelheim International GmbH Business Overview
  52. 7.9.3 Boehringer Ingelheim International GmbH Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Boehringer Ingelheim International GmbH Angina Pectoris Medication Product Portfolio
  54. 7.9.5 Boehringer Ingelheim International GmbH Recent Developments
  55. 7.10 Bayer AG
  56. 7.10.1 Bayer AG Company Information
  57. 7.10.2 Bayer AG Business Overview
  58. 7.10.3 Bayer AG Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bayer AG Angina Pectoris Medication Product Portfolio
  60. 7.10.5 Bayer AG Recent Developments
  61. 7.11 Amgen Inc.
  62. 7.11.1 Amgen Inc. Company Information
  63. 7.11.2 Amgen Inc. Business Overview
  64. 7.11.3 Amgen Inc. Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Inc. Angina Pectoris Medication Product Portfolio
  66. 7.11.5 Amgen Inc. Recent Developments
  67. 7.12 AstraZeneca
  68. 7.12.1 AstraZeneca Company Information
  69. 7.12.2 AstraZeneca Business Overview
  70. 7.12.3 AstraZeneca Angina Pectoris Medication Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca Angina Pectoris Medication Product Portfolio
  72. 7.12.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Angina Pectoris Medication Revenue (2021-2032)
  2. 8.2 North America Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 8.2.1 North America Angina Pectoris Medication Revenue by Type (2021-2026)
  4. 8.2.2 North America Angina Pectoris Medication Revenue by Type (2027-2032)
  5. 8.3 North America Angina Pectoris Medication Revenue Share by Type (2021-2032)
  6. 8.4 North America Angina Pectoris Medication Revenue by Application (2021-2032)
  7. 8.4.1 North America Angina Pectoris Medication Revenue by Application (2021-2026)
  8. 8.4.2 North America Angina Pectoris Medication Revenue by Application (2027-2032)
  9. 8.5 North America Angina Pectoris Medication Revenue Share by Application (2021-2032)
  10. 8.6 North America Angina Pectoris Medication Revenue by Country
  11. 8.6.1 North America Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Angina Pectoris Medication Revenue by Country (2021-2026)
  13. 8.6.3 North America Angina Pectoris Medication Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Angina Pectoris Medication Revenue (2021-2032)
  2. 9.2 Europe Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 9.2.1 Europe Angina Pectoris Medication Revenue by Type (2021-2026)
  4. 9.2.2 Europe Angina Pectoris Medication Revenue by Type (2027-2032)
  5. 9.3 Europe Angina Pectoris Medication Revenue Share by Type (2021-2032)
  6. 9.4 Europe Angina Pectoris Medication Revenue by Application (2021-2032)
  7. 9.4.1 Europe Angina Pectoris Medication Revenue by Application (2021-2026)
  8. 9.4.2 Europe Angina Pectoris Medication Revenue by Application (2027-2032)
  9. 9.5 Europe Angina Pectoris Medication Revenue Share by Application (2021-2032)
  10. 9.6 Europe Angina Pectoris Medication Revenue by Country
  11. 9.6.1 Europe Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Angina Pectoris Medication Revenue by Country (2021-2026)
  13. 9.6.3 Europe Angina Pectoris Medication Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Angina Pectoris Medication Revenue (2021-2032)
  2. 10.2 China Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 10.2.1 China Angina Pectoris Medication Revenue by Type (2021-2026)
  4. 10.2.2 China Angina Pectoris Medication Revenue by Type (2027-2032)
  5. 10.3 China Angina Pectoris Medication Revenue Share by Type (2021-2032)
  6. 10.4 China Angina Pectoris Medication Revenue by Application (2021-2032)
  7. 10.4.1 China Angina Pectoris Medication Revenue by Application (2021-2026)
  8. 10.4.2 China Angina Pectoris Medication Revenue by Application (2027-2032)
  9. 10.5 China Angina Pectoris Medication Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Angina Pectoris Medication Revenue (2021-2032)
  2. 11.2 Asia Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 11.2.1 Asia Angina Pectoris Medication Revenue by Type (2021-2026)
  4. 11.2.2 Asia Angina Pectoris Medication Revenue by Type (2027-2032)
  5. 11.3 Asia Angina Pectoris Medication Revenue Share by Type (2021-2032)
  6. 11.4 Asia Angina Pectoris Medication Revenue by Application (2021-2032)
  7. 11.4.1 Asia Angina Pectoris Medication Revenue by Application (2021-2026)
  8. 11.4.2 Asia Angina Pectoris Medication Revenue by Application (2027-2032)
  9. 11.5 Asia Angina Pectoris Medication Revenue Share by Application (2021-2032)
  10. 11.6 Asia Angina Pectoris Medication Revenue by Country
  11. 11.6.1 Asia Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Angina Pectoris Medication Revenue by Country (2021-2026)
  13. 11.6.3 Asia Angina Pectoris Medication Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Angina Pectoris Medication Revenue (2021-2032)
  2. 12.2 SAMEA Angina Pectoris Medication Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Angina Pectoris Medication Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Angina Pectoris Medication Revenue by Type (2027-2032)
  5. 12.3 SAMEA Angina Pectoris Medication Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Angina Pectoris Medication Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Angina Pectoris Medication Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Angina Pectoris Medication Revenue by Application (2027-2032)
  9. 12.5 SAMEA Angina Pectoris Medication Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Angina Pectoris Medication Revenue by Country
  11. 12.6.1 SAMEA Angina Pectoris Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Angina Pectoris Medication Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Angina Pectoris Medication Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst